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DOI: http://dx.doi.org/10.1016/j.hemonc.2014.12.001Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is a rare autosomal recessive disorder.
The mutation in the ECGF1 gene causes severe deficiency of thymidine phosphorylase (TP), which in turn
increases thymidine and deoxyuridine in the blood, serum, and tissue. The toxic levels of these products
cause malfunction of the mitochondrial respiratory chain and mitochondrial DNA. Commonly, patients
become symptomatic between 15 and 20 years of age (range 5 months to 35 years). The most commonly
affected systems are gastrointestinal, followed by ocular, and nervous system. The disease is often fatal;
high mortality rate is reported between 20 and 40 years of age. Treatment modalities that can increase
thymidine phosphorylase activity and decrease thymidine and deoxy-uridine have shown symptomatic
improvements in patients with MNGIE. Platelet transfusion, hemodialysis, peritoneal dialysis or alloge-
neic hematopoietic stem cell transplantation (HSCT) have been tried. The survival and long-term benefits
of these measures are still not clear. Engrafted patients after stem cell transplantation have showed
improvements in serum thymidine and deoxyuridine. We are reporting a case of MNGIE from Saudi Ara-
bia, who underwent allogeneic hematopoietic stem cell transplantation. No MNGIE case has been pre-
viously reported from Saudi Arabia or the Gulf Arab countries. From the available literature, so far
only 11 patients with MNGIE have undergone stem cell transplantation.
KEYWORDS: Mitochondrial neurogastrointestinal encephalomyopathy; MNGIE; Stem cell transplantation; Bone
marrow transplantationINTRODUCTIONMitochondrial neurogastrointestinal enceph-alomyopathy (MNGIE) is a rare autosomalrecessive disorder characterized by severe
muscle wasting, gastrointestinal dysmotility, leukoen-
cephalopathy, peripheral neuropathy, and ophthalmo-
plegia.1 The mutations in the ECGF1 gene encoding
thymidine phosphorylase (TP) cause alterations in
the respiratory chain and mitochondrial DNA(mtDNA).2 The prognosis of this disease is limited;
most patients die by the age of 35 years, but survival
may range from 15 to 54 years.1
Excessive thymidine alters mitochondrial nucleo-
side and nucleotide pools leading to impaired mito-
chondrial DNA replication, repair, or both. There
is an assumption that therapies that can reduce thymi-
dine levels might be helpful to MNGIE patients.3 In a
limited number of patients, treatment modalities such
as platelet transfusion, hemodialysis, and peritoneal85
86
case report MNGIE
dialysis or stem cell transplantation were tried. The
long-term beneﬁt of these treatments for MNGIE
is not clear.4–6 We report the ﬁrst case of MNGIE
fromSaudi Arabia and theGulf Arab states, andworld-
wide the 12th case ofMNGIE treated with hematopoi-
etic stem cell transplantation (HSCT). However, our
patient died on day 24 after transplantation.CASE REPORT
A 26-year-old male had been suffering from watery
diarrhea and abdominal pain over a period of
15 years. There was no history of bleeding per rec-
tum, melena or steatorrhoea. Abdominal pain was
scattered all over the abdomen and was mild in sever-
ity without any pattern, relieving or aggravating fac-
tors. He had difﬁculty in swallowing on a few
occasions. Appetite was normal with no history of
fever. The patient was a teetotaler and had no prior
sexual exposure or drug addictions. The patient
denied history of seizures, headache, arthralgia,
chronic cough, chest pain or dyspnoea. He was
unmarried and unemployed.
A physical examination showed severe muscle
wasting. His body mass index was 12 kg/m2. The
patient was pale. Findings on physical examination
included severe sensory and motor peripheral neurop-
athy of upper and lower limbs; bilateral sensory neural
deafness; mild ptosis of the left eye; and ophthalmo-
plegia. Cardiovascular, respiratory and abdominal
examinations were unremarkable.
Patient had consanguineous parents. He had eight
brothers and three sisters; two of them had died in
road accidents. One sister and another brother diedFigure 1. Pedigree diagram of the family tree showof similar illnesses (chronic diarrhea and muscle wast-
ing). Another sister had chronic diarrhea and muscle
wasting, and has been diagnosed with MNGIE. Fig-
ure 1 shows the pedigree diagram of the family tree.
On admission, laboratory results were as follows:
hemoglobin 104 gm/L (135–180); creatinine
40 lmol/L (64–115); potassium 2.8 mmol/L (3.5–5);
calcium 1.3 mmol/L (2.1–2.6); magnesium
0.23 mmol/L (0.70–1); albumin 27 gm/L (32–48);
phosphate 0.78 mmol/L (0.8–1.45); lactic acid
4.3 mmol/L (0.5–2); pyruvic acid 217 lmol/L (30–
90); ALT 13 U/L (10–45); LDH 306 U/L (135–
225); vitamin B6 < 3.5 lgm/L (4.5–60.6); vitamin E
3.5 mg/L (5.5–15.5); copper 2.6 lmol/L (11–22);
zinc 10.2 lmol/L (10.6–19); anti tissue trans-gluta-
minase 8.9 units (0–20); CRP 0.2 mg/L.
Urine thymidine was 72 mmol/mol and plasma
thymidine 15289 nano-mols/L (Normal < 700 nano-
mols/L). (Baylor Medical Genetics Laboratories;
Texas).
The stool examination for ova, parasites, and
stool for Clostridium difﬁcile were negative. Celiac
serology, serum QuantiFERON test, puriﬁed pro-
tein derivative (PPD) skin test and serology for
HIV 1 and 2 were negative. A CT scan of the
chest and abdomen with and without contrast
showed mild thickening of the terminal ileum, but
normal liver, pancreas, adrenals, and other organs.
The upper endoscopy showed features of reﬂux
esophagitis. The biopsy from the second part of
the duodenum was normal. The colonoscopy
revealed narrowed ileocaecal valve, and biopsy from
that area and the terminal ileum was normal. The
capsule endoscopy was also normal.ing autosomal recessive pattern of inheritance.
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Figure 2. High-resolution esophageal manometry images demonstrating severely impaired esophageal motility.
MNGIE case reportThe manometry study of the esophagus (Figure 2)
showed severe dysmotility of the esophagus. Gastric
emptying was signiﬁcantly delayed for emptying of
solid food with a T-1/2 of 101 min.
The nerve conduction study showed severe periph-
eral sensory-motor neuropathy, demyelinating in type
with secondary axonal degeneration. Tympanometry
was normal. Audiometry (Figure 3) conﬁrmed severe
bilateral sensory neural deafness. The visual evokedFigure 3. Audiometry images revealing
Hematol Oncol Stem Cell Ther 8(2) Second Quarter 2015potential after black and white square pattern reversal
stimulation of the right and left eye, in turn recorded
from the mid occipital region, were prolonged.
Electromyography (EMG) needle study of the dis-
tal and proximal muscles showed signiﬁcant neuro-
genic changes in the distal muscle with pronounced
signs of a chronic partial denervation with signs of
reinnervation. In the proximal muscle, the EMG
needle study showed more myopathic changes.severe bilateral sensory deafness.
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Sympathetic skin responses were absent after electri-
cal stimulation of contra-lateral median nerve. Absent
sympathetic skin response from left plantar skin was
also noted after right tibial nerve stimulation.
Electroencephalogram (EEG) showed a few short
runs of low voltage 5 Hz activity temporally with shift
to left-side predominance during drowsiness and
hyperventilation. A Magnetic resonance imaging
(MRI) of the brain (Figure 4) showed typical ﬁndings
of leukoencephalopathy.
The genetic study was carried out by Baylor Col-
lege of Medicine, Medical Genetics Laboratories,
Houston, Texas. The TYMP sequence analysis
(TYMP gene encode thymidine phosphorylase
enzyme) showed homozygous novel missense muta-
tion, c 833G > A (P G278D) mutation at exon 7
location.
A diagnosis of mitochondrial neurogastrointestinal
encephalomyopathy (MNGIE) was made in our
patient.
Total parental nutrition was given to improving
his inadequate nutritional status, but the patient did
not gain weight. After a few months’ stay in the hos-
pital, the patient underwent hematopoietic stem cell
transplantation (HSCT). The patient’s Karnofsky
score was 50 (range 0–100) before HSCT. The
patient’s source of stem cells was granulocyte col-
ony-stimulating factor (G-CSF) stimulated bone mar-
row of HLA-identical male sibling donor.
The conditioning regimens for stem cell transplan-
tation were busulfan and ﬂudarabine. Busulfan
was given through intravenous route as dose of
0.8 mg/kg, six hourly for three consecutive days.Figure 4. MRI of the brain showing features of leukoencephalopathy.The ﬁrst dose of busulfan was given four days prior
to bone marrow transplantation (BMT). Fludarabine
was given at a dose of 25 mg/m2 daily; the ﬁrst dose
was started nine days prior to BMT, and then given
daily for a total of ﬁve days.
Graft versus host disease (GVHD) prophylaxis
was the standard dose of methotrexate/cyclosporine.
The absolute neutrophil count (ANC) engraftment
happened on day 16 post-BMT and platelet engraft-
ment on day 19 post-BMT.
Post-HSCT period was uneventful until day 17.
The frequency of diarrhea improved following
HSCT. On day 17, the patient developed a skin rash
that was due to drug allergy. On day 23 post-BMT,
the patient’s temperature spiked. Within a few hours,
the patient developed respiratory failure and hypoten-
sion with features of septic shock and multi-organ
failure. Bronchoscopy showed copious secretion from
the respiratory tracts, and culture was positive for
Klebsiella pneumonia. The patient was given appro-
priate antimicrobials and other supportive measures.
On day 24 post-HSCT, the patient died of multi-
organ failure secondary to sepsis. Biochemical and
clinical improvement of the patient following HSCT
was not established.DISCUSSION
Okamura initially described MNGIE in 1976.7 It is a
well-characterized autosomal recessive disorder. Most
of the patients have gastrointestinal dysmotility,
cachexia, peripheral neuropathy, and diffuse leukoen-
cephalopathy.8 Though other diseases can have differ-
ent clinical features that are seen in MNGIE, diffuse
leukoencephalopathy is typical for MNGIE.1,9
Age of onset and sequence of organ involvement
can vary considerably. Gastrointestinal (GI) symp-
toms are the initial symptoms in half of the patients.
Often, GI symptoms are mistaken for irritable
bowel syndrome, inﬂammatory bowel disease, celiac
disease or other GI diseases. Similarly, peripheral
neuropathy can be mistaken for chronic inﬂammatory
demyelinating polyneuropathy or demyelinating forms
of Charcot-Marie-Tooth disease. Unexplained malab-
sorption syndrome in association with neuropathy
and leukoencephalopathy should prompt the physi-
cian to screen thymidine phosphorylase activity.1
MNGIE can present atypically and with phenotypic
variation.10
Leukoencephalopathy is clinically silent, but some
patients can have mild neurological symptoms such
as headache, seizure, cognitive impairment, dementia,
or psychiatric symptoms. MRI ﬁndings of theHematol Oncol Stem Cell Ther 8(2) Second Quarter 2015
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leukoencephalopathy appears as hyperintense on T2-
weighted or ﬂuid-attenuated inversion recovery
images. In the early stages of the condition, these
results may be patchy, but eventually become diffuse
and conﬂuent.1
From a review of a cohort of 102 MNGIE patients
collected from 1988 to 2011, signiﬁcant mortality was
reported between the ages of 20 and 40 years.1 In
1999, Nishino et al identiﬁed the gene mutation
responsible for MNGIE. They identiﬁed the respon-
sible mutation of MNGIE as homozygous or com-
pound heterozygous mutations in the gene
specifying thymidine phosphorylase (TP), located on
chromosome 22q13.32-qter. The mutation leads to
extremely low activity of TP in leukocytes.11
Very low TP activity eventually ends up in sys-
temic accumulation of thymidine and deoxyuridine
that causes mitochondrial DNA instability.4 Treat-
ments that can achieve the restoration of TP activity
might be possible options. The in-vitro experiment by
Laura et al with platelet transfusion in two patients
partially restored TP catabolism of thymidine and
deoxyuridine in both patients. The infused platelets
provided TP activity, and the effect should be
transient.
Spinazzola and team tried hemodialysis in another
two MNGIE patients in 2002. Patient A underwent
one dialysis, and patient B underwent three consecu-
tive weekly dialysis treatments. Hemodialysis reduced
circulating concentrations of thymidine in both
patients. However, the effect was transient. Three
hours after dialysis, levels of the nucleoside returned
to pretreatment values.3 In 2006, there was another
attempt to reduce the blood thymidine level with
hemodialysis in a patient with MNGIE. A signiﬁcant
reduction in thymidine levels in the plasma and urine
was observed during and after dialysis. However, the
researchers noted a progressive reduction of the initial
thymidine level after several dialysis trials.5
In 2007, a 16-year-old girl with MNGIE was trea-
ted with continuous ambulatory peritoneal dialysis for
three years. She showed marked improvements in her
symptoms. While she was on dialysis, her vomiting
and abdominal pain improved, and she had a weight
gain of 5 kg. Interruption of dialysis returned the
symptoms.12
In 2006, Hirano et al. performed allogeneic stem
cell transplantation to correct biochemical derange-
ments in two MNGIE patients. Patient A had pri-
mary non-engraftment of donor cells with
spontaneous autologous recovery. After 86 days ofHematol Oncol Stem Cell Ther 8(2) Second Quarter 2015transplantation, this patient died from disease pro-
gression complicated by sepsis and respiratory failure.
At 6.5 months after the transplant, Patient B reported
less severe abdominal pain, improved swallowing abil-
ity, and decreased numbness in her hands and feet. In
both patients, improvement of TP activity and reduc-
tion of thymidine and deoxyuridine was observed.6
Between 2007 and 2009, seven more MNGIE
patients were treated with hematopoietic stem cell
transplantation. The data of the post-transplant
engrafted patients suggest biochemical recovery of
the TP activity, but the clinical usefulness of trans-
plantation was difﬁcult to judge because of short
observation period.13
In 2012, two more MNGIE patients underwent
HSCT. Both patients achieved full donor chimerism,
and in both, improvements of TP activity and
decrease in urine nucleoside concentration was
observed. Both patients showed improvement in gas-
trointestinal dysmotility, abdominal cramps and diar-
rhea post-HSCT. Neurological assessment remained
unchanged. However, the ﬁrst patient died 15 months
after HSCT due to gastrointestinal obstruction and
shock; the second patient died eight months after
the procedure due to respiratory distress following
septic shock.14
Worldwide, so far twelve patients have undergone
HSCT for MNGIE, including our patient from
Saudi Arabia. In engrafted patients, an improvement
in biochemical parameters of MNGIE was noted.
The 12 patients who had undergone HSCT for
MNGIE did not survive for a long period. With avail-
able information, the long-term beneﬁt of bone mar-
row transplantation in MNGIE is still unknown.
Often, MNGIE patients are diagnosed at an advanced
stage. Identifying these patients at a younger age and
offering them HSCT might improve their quality of
life and survival.
In conclusion, we have reported a case of MNGIE,
a disease which is often fatal. Stem cell transplanta-
tion is considered one treatment modality. More
study is required to conﬁrm the role of transplanta-
tion in improving the patient’s well-being and chances
of survival. Awareness of this disease among physi-
cians is essential so that these patients are diagnosed
early and experimental treatment can be offered
before they reach an irreversible state.CONFLICT OF INTEREST
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